Cargando…

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechanism of ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayes-Genis, Antoni, Iborra-Egea, Oriol, Spitaleri, Giosafat, Domingo, Mar, Revuelta-López, Elena, Codina, Pau, Cediel, Germán, Santiago-Vacas, Evelyn, Cserkóová, Adriana, Pascual-Figal, Domingo, Núñez, Julio, Lupón, Josep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187349/ https://www.ncbi.nlm.nih.gov/pubmed/34103605 http://dx.doi.org/10.1038/s41598-021-91546-z

Ejemplares similares

Gender-Related Differences in Heart Failure Biomarkers
por: Cediel, Germán, et al.
Publicado: (2021)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality
por: Spitaleri, Giosafat, et al.
Publicado: (2022)

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study
por: Domingo, Mar, et al.
Publicado: (2021)

Quality of life in patients with heart failure and improved ejection fraction: one‐year changes and prognosis
por: Zamora, Elisabet, et al.
Publicado: (2022)

Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
por: Spitaleri, Giosafat, et al.
Publicado: (2021)

Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators
por: Codina, Pau, et al.
Publicado: (2022)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Translational proteomics in cardiogenic shock: from benchmark to bedside
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study
por: Revuelta‐López, Elena, et al.
Publicado: (2020)

Different Effects on Protein Expression of CDR132L, an Antisense Inhibitor of miR-132, and Standard Therapies for Myocardial Infarction
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Commentary: A Review of Prognosis Model Associated With Cardiogenic Shock After Acute Myocardial Infarction
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
por: Rodríguez-Calvo, Ricardo, et al.
Publicado: (2023)

Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
por: del Carmen Asensio Lopez, Maria, et al.
Publicado: (2020)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
por: Asensio Lopez, Maria del Carmen, et al.
Publicado: (2020)

Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
por: Domingo, Mar, et al.
Publicado: (2020)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Pascual-Figal, Domingo, et al.
Publicado: (2021)

Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
por: Julián, María Teresa, et al.
Publicado: (2020)

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation
por: Abdul-Jawad Altisent, Omar, et al.
Publicado: (2021)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Determination of HLA‐A, ‐B, ‐C, ‐DRB1 and ‐DQB1 allele and haplotype frequencies in heart failure patients
por: Roura, Santiago, et al.
Publicado: (2019)

Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme
por: Gastelurrutia, Paloma, et al.
Publicado: (2016)

Can Natriuretic Peptides be Used to Guide Therapy?
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
por: Iborra-Egea, Oriol, et al.
Publicado: (2017)

Circulating monocyte subsets and heart failure prognosis
por: Elchinova, Elena, et al.
Publicado: (2018)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Impact of a ‘stent for life’ initiative on post‐ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience
por: Bayes‐Genis, Antoni, et al.
Publicado: (2017)

Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
por: Aimo, Alberto, et al.
Publicado: (2022)

The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients
por: Pacho, Cristina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jjdlbs32fpdk1ltcfmgvip2pvo